CheckmAb Srl is an innovative start-up biotech company focused on the development of novel monoclonal antibodies for cancer immunotherapy, with the aim to provide safer and more effective therapies for patients. At present, the company is focused on the development of monoclonal antibodies for cancer immunotherapy, specifically targeting tumor-infiltrating regulatory T lymphocytes. These antibodies are expected to unleash the immunological response only within the neoplastic lesion, thereby avoiding harmful systemic autoimmune reactions that are too often associated with current immuntoherapies.
| Website | http://www.checkmab.eu/ |
| Revenue | $1 million |
| Employees | 11 (7 on RocketReach) |
| Founded | 2018 |
| Address | Via Francesco Sforza, 35, Padiglione Romeo ed Enrica Invernizzi, Milan, Lombardy 20122, IT |
| Phone | +39 02 0066 0220 |
| Technologies |
JavaScript
,
HTML
,
PHP
+12 more
(view full list)
|
| Industry | Biotechnology Research, Business Services General, Business Services |
| Keywords | Monoclonal Antibodies, Cancer Immunotherapy, Biotechnology, Immunotherapy, Pharmaceutical, Biotech, Drug Development, Cancer Treatment, Oncology, Therapeutic Antibodies, Clinical Trials, Cancer Research, Pharmaceutical Research, Biopharmaceutical, Drug Discovery, Precision Medicine, Targeted Therapy, Innovative Therapies, Novel Therapeutics |
| Competitors | Nordstrom, Macy's, H&M, Forever 21, Zalando, ASOS.com, REVOLVE, Zappos Family of Companies, Bonobos, UNIQLO Australia +42 more (view full list) |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 54 Companies |
Looking for a particular Checkmab S.r.l. employee's phone or email?
The Checkmab S.r.l. annual revenue was $1 million in 2026.
Marco Venturelli is the Chairman of Checkmab S.r.l..
7 people are employed at Checkmab S.r.l..
Checkmab S.r.l. is based in Milan, Lombardy.
The NAICS codes for Checkmab S.r.l. are [541, 54].
The SIC codes for Checkmab S.r.l. are [87, 873].